The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

Authors :: Holt, B. (Bronno) van der
Löwenberg, B. (Bob)
Burnett, A.K. (Alan)
Knauf, W.U. (Wolfgang)
Shepherd, J. (John)
Piccaluga, P.P.
Ossenkoppele, G.J. (Gert)
Verhoef, G.E.G. (Gregor)
Ferrant, A. (Augustin)
Crump, M.
Selleslag, D.
Theobald, M. (Matthias)
Fey, M. (Martin)
Vellenga, E. (Edo)
Dugan, M.
Sonneveld, P. (Pieter)
Holt, B. (Bronno) van der
Löwenberg, B. (Bob)
Burnett, A.K. (Alan)
Knauf, W.U. (Wolfgang)
Shepherd, J. (John)
Piccaluga, P.P.
Ossenkoppele, G.J. (Gert)
Verhoef, G.E.G. (Gregor)
Ferrant, A. (Augustin)
Crump, M.
Selleslag, D.
Theobald, M. (Matthias)
Fey, M. (Martin)
Vellenga, E. (Edo)
Dugan, M.
Sonneveld, P. (Pieter)
Publication Year :: 2005
Abstract: To determine whether MDR1 reversal by the addition of the P-glycoprotein (P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve event-free survival (EFS), 419 untreated patients with acute myeloid leukemia (AML) aged 60 years and older were randomized to receive 2 induction cycles of daunorubicin and cytarabine with or without PSC-833. Patients in complete remission were then given 1 consolidation cycle without PSC-833. Neither complete respo

Full Text Access

Tools